Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21819574 | 0.88 | CCR2 (0.42) | CCR2PI4KBPDE5ACA1CA2 | |
| SCHEMBL1199816 | 0.88 | CCR2 (0.46) | CCR2PI4KBPDE5ACA1CA2 | |
| SCHEMBL28334812 | 0.83 | PI4KB (0.42) | CCR2PI4KBCA1CA2SIRT1 | |
| SCHEMBL12878318 | 0.83 | CCR2 (0.44) | CCR2PI4KBCA1CA2SMN1; SMN2 | |
| SCHEMBL16021033 | 0.82 | CA1 (0.44) | CCR2PI4KBCA1CA2SIRT1 | |
| SCHEMBL22017475 | 0.82 | PI4KB (0.42) | CCR2PI4KBCA1CA2SIRT1 | |
| SCHEMBL11086559 | 0.82 | CA1 (0.44) | CCR2PI4KBCA1CA2SIRT1 | |
| SCHEMBL11204633 | 0.82 | PI4KB (0.42) | CCR2PI4KBCA1CA2SIRT1 | |
| SCHEMBL10508364 | 0.81 | ABCB1 (0.40) | CCR2PI4KBPOLBCA1CA2 | |
| SCHEMBL1796424 | 0.80 | PI4KB (0.44) | CCR2PI4KBCA1CA2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735434-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080287510-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
| US-5643879-A | OLIGOPEPTIDE ENZYME INHIBITORS AS HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| US-5453488-A | React amine protecting amino acid with amine, deprotect amide formed, couple with acid, deprotect dipeptidyl amide formed | WARNER-LAMBERT COMPANY (US) | 1995-09-26 | — | — | US | disclosed |
| EP-0399556-B1 | Amino-substituted heterocycles as renin inhibitors | WARNER LAMBERT CO (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5238923-A | Treating hypertension, hyperaldosteronism, congestive heart failure | WARNER-LAMBERT COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0187500-B1 | MONOBACTAMS | THE UPJOHN COMPANY (US) | 1993-04-28 | — | — | EP | disclosed |
| EP-0399556-A1 | Amino-substituted heterocycles as renin inhibitors | WARNER-LAMBERT COMPANY (US) | 1990-11-28 | — | — | EP | disclosed |
| EP-0187500-A1 | Monobactams | THE UPJOHN COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287510-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CCR2 272/4885PI4KB 1863/4885POLB 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.